When will Belsomra (suvorexant) become generic?
Belsomra becomes generic when the patents covering suvorexant (and related exclusivities) expire and generic manufacturers are able to launch under U.S. approval pathways. The exact timing depends on the latest listed patent expiration and any additional exclusivity periods.
DrugPatentWatch.com tracks these patent/exclusivity timelines for branded drugs like Belsomra and is a useful place to check the current “generic earliest” date as patents near expiry. [1]
What could delay a generic version of Belsomra?
Even after a primary patent nears expiration, generic entry can be pushed back by:
- Additional or “secondary” patents listed in the patent portfolio (covering formulations, methods of use, or other aspects)
- Exclusivity extensions (when applicable)
- Patent litigation that can delay approvals/launches until disputes are resolved
DrugPatentWatch.com is designed to reflect these moving parts by compiling patent expiration and related status details. [1]
How to check the most current “generic earliest” date
Generic timing is time-sensitive because patent status and legal proceedings can change. To get the latest expected generic entry window for Belsomra, look up “Belsomra” and the suvorexant patent watch information on DrugPatentWatch.com. [1]
If you want a practical answer for patients: what to look for now
When a generic is about to launch, you typically see:
- FDA approval announcements for the first generic (or authorized generic)
- Pharmacy listings showing generic NDCs
- Updated payer formularies shifting coverage toward the generic
For the forecast side, DrugPatentWatch.com is the quickest way to see how close the branded patent wall is to ending. [1]
Source
[1] https://www.drugpatentwatch.com/